Loading...
•
Mar 31, 2025
Day One Q1 2025 Earnings Report
Day One reported first quarter 2025 financial results and corporate progress.
Key Takeaways
Day One Biopharmaceuticals reported Q1 2025 financial results showing total revenue of $30.8 million, driven by OJEMDA net product revenue of $30.5 million. The company's net loss was $36.0 million, an improvement from the previous year. Day One ended the quarter with $473.0 million in cash, cash equivalents, and short-term investments.
OJEMDA net product revenue reached $30.5 million in Q1 2025.
Total revenues for the quarter were $30.8 million.
Net loss for Q1 2025 was $36.0 million.
The company held $473.0 million in cash, cash equivalents, and short-term investments as of March 31, 2025.
Revenue by Segment
Forward Guidance
The report did not contain explicit forward guidance for specific financial metrics.
Positive Outlook
- Regulatory filing for tovorafenib accepted by the European Medicines Agency.
- DAY301 cleared the first dose cohort in Phase 1a trial.
- Pivotal Phase 3 FIREFLY-2 clinical trial expected to be fully enrolled in H1 2026.
- Presented positive preclinical data on sequencing MEK inhibitor therapy after tovorafenib at AACR.
- Presented clinical trial-in-progress poster for DAY301 at AACR.
Challenges Ahead
- No specific negative forward-looking statements were provided in the report.
- No specific negative forward-looking statements were provided in the report.
- No specific negative forward-looking statements were provided in the report.
- No specific negative forward-looking statements were provided in the report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...